ReviewExpert opinion on biological therapy2010
Bapineuzumab.
Review in Expert opinion on biological therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 83 citations in OpenAlex.
- Trial
- Monoclonal Antibody Therapy in Alzheimer's Disease.Pharmaceutics · 2023Review
- Effectiveness and safety of monoclonal antibodies against amyloid-betaFrontiers in neurology · 2023Article
- Therapy for Alzheimer's disease: Missing targets and functional markers?Ageing research reviews · 2021Review
- Passive immunotherapies targeting Aβ and tau in Alzheimer's disease.Neurobiology of disease · 2020Review
- Both Amyloid-β Peptide and Tau Protein Are Affected by an Anti-Amyloid-β Antibody Fragment in Elderly 3xTg-AD Mice.International journal of molecular sciences · 2020Article
- Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.Neurobiology of disease · 2020Review
- Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology.Molecular neurobiology · 2019Article
- Amyloid β oligomers (AβOs) in Alzheimer's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2018Review
- Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer's Disease Immunotherapy.Drugs & aging · 2016Review
- Automated Hippocampal Subfield Segmentation at 7T MRI.AJNR. American journal of neuroradiology · 2016Article
- Amyloid β oligomers in Alzheimer's disease pathogenesis, treatment, and diagnosis.Acta neuropathologica · 2015Review
- Development of Immunoassays for the Quantitative Assessment of Amyloid-β in the Presence of Therapeutic Antibody: Application to Pre-Clinical Studies.Journal of Alzheimer's disease : JAD · 2015Article
- White matter changes in dementia: role of impaired drainage of interstitial fluid.Brain pathology (Zurich, Switzerland) · 2015Review
- Advances in recent patent and clinical trial drug development for Alzheimer's disease.Pharmaceutical patent analyst · 2014Review
- Failure of perivascular drainage of β-amyloid in cerebral amyloid angiopathy.Brain pathology (Zurich, Switzerland) · 2014Article
- Innovating aging: promises and pitfalls on the road to life extension.Gerontology · 2014Article
- Immunogenicity of DNA- and recombinant protein-based Alzheimer disease epitope vaccines.Human vaccines & immunotherapeutics · 2014Review
- Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics.Alzheimer's research & therapy · 2014Review
- Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology.The Journal of biological chemistry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
importance of the fieldAlzheimer's disease is the leading cause of dementia in the elderly, and there is no disease-modifying therapy yet available. Immunotherapy directed against the beta-amyloid peptide may be capable of slowing the rate of disease progression. Bapineuzumab, an anti-beta-amyloid monoclonal antibody, will be the first such agent to emerge from Phase III clinical trials. AREAS COVERED IN THIS REVIEW: The primary literature on bapineuzumab from 2009 and 2010 is reviewed in its entirety, along with the literature on AN1792, a first-generation anti-beta-amyloid vaccine, from 2003 to 2009. Other Alzheimer's disease immunotherapeutics currently in development, according to www.clinicaltrials.gov , are also discussed. WHAT THE READER WILL GAIN: In addition to a critical appraisal of the Phase II trial results for bapineuzumab, this review considers the broader field of immunotherapy for Alzheimer's disease as a whole, including the challenges ahead. TAKE HOME MESSAGE: Bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease. However, particularly in APOE 4 carriers, its ability to slow disease progression remains uncertain, and vasogenic edema - a dose-limiting and potentially severe adverse reaction - may limit its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.